Effect of oral XXXX on esophageal stricture after complete circular endoscopic submucosal dissection for superficial esophageal squamous cell carcinoma: a case report.

@entity1 @entity1496 @entity390 @entity5 @entity384 @entity957 @entity189 @entity5848 @entity1820 @entity1282 @entity617
A 74-year-old @entity1 with @entity390 underwent upper @entity1820 was found in the middle thoracic esophagus. Histological examination with endoscopic biopsies revealed @entity957 ( @entity957 ), and chromoendoscopy with @entity1496 staining revealed that the superficial @entity957 involved nearly the entire circumference of the esophageal lumen. There were neither nodal nor distant metastases. @entity5848 (ESD) was successfully achieved with @entity5 -free margins in an en bloc fashion. The histopathological examination confirmed a diagnosis of @entity189 limited to the lamina propria mucosae without angiolymphatic invasion. Oral @entity617 was started with 0.5 mg/kg daily on the 3rd post-ESD day, tapered gradually, and then discontinued 8 weeks later without adverse effects. There were no complaints of @entity1282 following ESD. On follow-up endoscopy with @entity1496 staining, which was scheduled at 1, 3 and 6 months after ESD, there was no postprocedural esophageal stricture, and neither recurrent nor metachronous lesions were found. Thus, the @entity1 required no sessions of @entity384 . At the last outpatient clinic visit 7 months after ESD, he remained well without @entity1282 . Oral @entity617 administration may offer an effective therapeutic strategy to prevent the post-ESD esophageal stricture after complete circular ESD.
